The COBRA-REDUCE trial missed its primary endpoint, researchers reported on Sunday, after the Cobra PzF NanoCoated coronary stent (NCS) with 14-day-dual antiplatelet therapy (DAPT) failed to reduce bleeding versus standard drug-eluting stents (DES) and longer DAPT regimens at 6 months.